Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PST-2238 Sigma-Tau.

Sanjay Jain1

  • 1PGIMER, Department of Internal Medicine, Chandigarh, 160012, India. drsjain@glide.net.in

Idrugs : the Investigational Drugs Journal
|December 1, 2004
PubMed
Summary
This summary is machine-generated.

Sigma-Tau is developing PST-2238, a novel steroidal ATPase modulator, for hypertension treatment. Early-stage clinical trials were underway in 2002 to evaluate this potential new therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep learning‑based cell type prediction in lung tissue from brightfield histology using CODEX-derived labels.

Proceedings of SPIE--the International Society for Optical Engineering·2026
Same author

Benefits Beyond Hypertension Control: Current and Evolving Treatment Strategies for Prevention of Cardiovascular Diseases.

Current hypertension reviews·2026
Same author

Prescription practices and reasons for referral to tertiary care among patients with headache in India.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2026
Same author

DigitAb: Domain-Adaptive Cell Type Prediction Method from Light Microscopy Images.

bioRxiv : the preprint server for biology·2026
Same author

A MEF2C transcription factor network regulates proliferation of glomerular endothelial cells in diabetic kidney disease.

Kidney international·2026
Same author

Takayasu Retinopathy Findings on Ultra-Wide Field Fundus Fluorescein Angiography.

Ocular immunology and inflammation·2026
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Development

Background:

  • Hypertension remains a significant global health concern requiring novel therapeutic strategies.
  • Existing treatments for hypertension have limitations, necessitating the exploration of new drug classes.

Purpose of the Study:

  • To investigate the potential of PST-2238, a novel steroidal ATPase modulator, as a treatment for hypertension.
  • To assess the safety and efficacy of PST-2238 in early-phase clinical trials.

Main Methods:

  • Development of PST-2238, a prototype steroidal ATPase modulator.
  • Conducting Phase II clinical trials to evaluate the drug's therapeutic potential.

Main Results:

  • PST-2238 represents a new class of compounds targeting ATPase modulation.

Related Experiment Videos

  • Phase II trials for PST-2238 were in progress as of early 2002.

    • Conclusions:

    • PST-2238 shows promise as a potential new pharmacological agent for managing hypertension.
    • Further clinical evaluation is required to establish the efficacy and safety profile of PST-2238.